Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.

Rheumatology (Oxford, England)

Volumn 48, Issue 11, 2009, Pages 1451-1454

  Aringer, Martin ^a   Houssiau, Frederic ^a   Gordon, Caroline ^a   Graninger, Winfried B ^a   Voll, Reinhard E ^a   Rath, Eva ^a   Steiner, Guenter ^a   Smolen, Josef S ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MIDDLE AGED; MULTICENTER STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73349117550     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep270     Document Type: Article

References (0)